MSD’s Keytruda use in adenocarcinoma could be limited based on biomarker
Pharmaceutical Technology
JUNE 16, 2023
In 2021, as part of the same Keynote-811 trial, the US Food and Drug Administration (FDA) granted accelerated approval to Keytruda for treating locally advanced unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma, in combination with trastuzumab and chemotherapy containing fluoropyrimidin and platinum.
52 
Let's personalize your content